Navigation Links
Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program

PARK CITY, Utah, July 30 /PRNewswire-FirstCall/ -- Nutraceutical International Corporation (Nasdaq: NUTR) today reported results for the fiscal 2009 third quarter ended June 30, 2009. Net sales for the fiscal 2009 third quarter were $39.4 million compared to $40.5 million for the same quarter of fiscal 2008. For the third quarter of fiscal 2009, net income was $3.0 million, or $0.27 diluted earnings per share, compared to net income of $2.9 million, or $0.26 diluted earnings per share, for the same quarter of fiscal 2008.

Net sales for the nine months ended June 30, 2009 were $121.0 million compared to $126.0 million for the same period in fiscal 2008. During the second quarter of fiscal 2009, the Company recorded a non-cash goodwill impairment charge of $37.5 million ($27.3 million after tax, or $2.51 per diluted share for the nine months ended June 30, 2009) resulting in a net loss of $(17.2) million, or $(1.58) per diluted share, for the nine months ended June 30, 2009, compared to net income of $10.4 million, or $0.93 per diluted share, for the same period of fiscal 2008. Excluding the non-cash impairment charge, net income for the nine months ended June 30, 2009 would have been $10.1 million, or $0.92 per diluted share.

Operating cash flow for the nine months ended June 30, 2009 was $17.2 million compared to $14.4 million for the same period of fiscal 2008. This operating cash flow was primarily used to invest $7.4 million in purchases of property and equipment and repay $9.5 million in net borrowings on the Company's revolving credit facility.

Bill Gay, chairman and chief executive officer, commented, "Domestic and international sales improved in the third quarter despite the current economic environment and we are hopeful that this trend will continue. Net income remained solid and cash flows increased as a result of inventory and accounts receivable reductions. Gross margins declined slightly due to increased raw material prices and manufacturing overhead costs related to inventory reductions. Selling, general and administrative expense reductions offset our lower gross margins. Our core health food store customers are regaining confidence in their businesses and we look forward to helping them grow. Ongoing sales promotions appear to be benefiting stores, consumers and our Company. We expect acquisitions to contribute to profitability and cash flow within this calendar year. It is encouraging that the market has responded favorably to the Company's recent addition to the Russell 2000 stock index and we believe our financial strength and position as a value based stock will bring awareness to many new investors."

Mr. Gay continued, "I am also pleased to announce that on July 28, 2009, our Board of Directors agreed to add an additional one million shares to our previously approved share purchase program which means the Company is authorized to buy up to 1.56 million total additional shares of our outstanding common stock." Under this approved share purchase program, the Company may purchase common stock from time to time on the open market and in individually negotiated transactions. The amount and timing of any purchases will be dependent upon a number of factors, including the price and availability of the Company's shares and general market conditions. The Company currently has approximately 10.9 million shares of its common stock outstanding. Since October 1, 2003, the Company has purchased approximately 1.3 million shares of its common stock at an average price of $13.61 per share for an aggregate purchase price of approximately $17.5 million.


We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate, from beginning to end, the manufacturing, marketing and distribution of branded nutritional supplement businesses in the natural products industry. We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

We sell branded nutritional supplements and other natural products under the trademarks Solaray(R), VegLife(R), KAL(R), Nature's Life(R), Sunny Green(R), Action Labs(R), Natural Balance(R), NaturalMax(R), bioAllers(R), Herbs for Kids((TM)), Natra-Bio(R), NaturalCare(R), Zand(R), Health from the Sun(R), Life-flo(R), Larenim(R), Living Flower Essences(R), Pioneer(R), Thompson(R), Natural Sport(R), Supplement Training Systems(R), Premier One(R), Montana Big Sky(TM), ActiPet(R), FunFresh Foods(TM), Dowd & Rogers(TM), CompliMed(R), AllVia(TM), Oakmont Labs(R), Healthway(R), Body Gold(R), Sayge(TM), Monarch Nutraceuticals(TM) and Great Basin Botanicals(TM). Under the name Woodland Publishing(TM), we publish, print and market a line of books and booklets to, among others, book distributors, national retail bookstores and health and natural food stores. We also distribute branded products of certain third parties.

We own neighborhood natural food markets, which operate under the trade names The Real Food Company (TM), Thom's Natural Foods(TM) and Cornucopia Community Market(TM). We also own health food stores, which operate under the trade names Fresh Vitamins(TM) and Granola's(TM).

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 4,000 SKUs, including over 700 SKUs sold internationally. We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although these statements are believed to be reasonable, they are inherently uncertain. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Press Release. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism or civil unrest, (iii) adverse publicity or negative consumer perception regarding nutritional supplements, (iv) changes in government regulations, (v) product liability claims and litigation, (vi) insurance coverage issues, (vii) increased competition or costs, (viii) intellectual property rights of other parties, (ix) the loss of key personnel, (x) disruptions from acquisitions, (xi) issues with obtaining raw materials of adequate quality or quantity, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) changes in general worldwide economic or political conditions, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) litigation generally, and (xvi) other factors indicated from time to time in our SEC reports, copies of which are available upon request from our investor relations group or which may be obtained at the SEC's website (

(C) 2009 Nutraceutical Corporation. All rights reserved.

                        (unaudited; dollars in thousands)

                                           June 30,   September 30,
                                          ---------  --------------
                                               2009            2008
      Current assets, net                   $49,719         $55,577
      Property, plant and equipment, net     55,232          52,356
      Goodwill                                  332          37,632
      Other non-current assets, net          25,503          16,099
                                             ------          ------
                                           $130,786        $161,664
                                           --------        --------

    Liabilities and Stockholders' Equity
      Current liabilities                   $14,425         $19,239
      Long-term liabilities                  19,929          28,965
      Stockholders' equity                   96,432         113,460
                                             ------         -------
                                           $130,786        $161,664
                                           --------        --------

             (unaudited; dollars in thousands, except per share data)

                                     Three months ended     Nine months ended
                                          June 30,               June 30,
                                     ------------------     -----------------
                                       2009       2008       2009        2008

    Net sales                        $39,406    $40,454   $120,992    $125,986
    Cost of sales                     19,250     18,489     56,964      57,192
                                      ------     ------     ------      ------
        Gross profit                  20,156     21,965     64,028      68,794
    Operating expenses
      Selling, general and
       administrative                 15,099     16,933     46,585      50,539
      Amortization of
       intangible assets                 163        185        480         522
      Impairment of goodwill               -          -     37,519           -
                                         ---        ---     ------         ---
    Income (loss) from operations      4,894      4,847    (20,556)     17,733
    Interest and other (income)
     expense, net                        177        223        951       1,008
                                         ---        ---        ---       -----
    Income (loss) before provision
     (benefit) for income taxes        4,717      4,624    (21,507)     16,725
    Provision (benefit) for
     income taxes                      1,698      1,771     (4,279)      6,309
                                       -----      -----     ------       -----

    Net income (loss)                 $3,019     $2,853   $(17,228)    $10,416
                                      ------     ------   --------     -------

    Net income (loss) per common
      Basic                            $0.28      $0.26     $(1.58)      $0.94
      Diluted                           0.27       0.26      (1.58)       0.93

    Weighted average common shares
      Basic                       10,903,394 10,964,696 10,874,382  11,043,026
      Diluted                     10,982,174 11,097,500 10,874,382  11,181,609

                               ADJUSTED EBITDA SCHEDULE
                          (unaudited; dollars in thousands)

                                     Three months ended      Nine months ended
                                           June 30,               June 30,
                                     ------------------      -----------------
                                      2009         2008       2009        2008

    Net income (loss)               $3,019       $2,853   $(17,228)    $10,416
    Provision (benefit) for
     income taxes                    1,698        1,771     (4,279)      6,309
    Interest and other (income)
     expense, net (1)                  177          223        951       1,008
    Depreciation and amortization    1,683        1,514      4,959       4,256
    Impairment of goodwill (2)           -            -     37,519           -
                                       ---          ---     ------         ---
     EBITDA                          $6,577      $6,361    $21,922     $21,989
                                     ------      ------    -------     -------

    (1)  Includes amortization of deferred financing fees.

    (2)  For the nine months ended June 30, 2009, a non-cash goodwill
         impairment charge of $37,519 was recorded related to our branded and
         natural food markets reporting units.

SOURCE Nutraceutical International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
2. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
3. Nutraceutical Reports Fiscal 2009 Q2 Results
4. Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health
5. Nutraceutical Reports Fiscal 2009 Q1 Results
6. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
7. Nutraceutical Reports 2008 Fiscal Year End Results
8. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
9. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
10. Nutraceuticals could prevent diabetes
11. Nutraceutical Reports Q3 Results
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology: